Angiographic and clinical outcomes of everolimus-eluting stent in the treatment of extra long stenoses (AEETES)

J Interv Cardiol. 2013 Feb;26(1):22-8. doi: 10.1111/joic.12006. Epub 2012 Dec 10.

Abstract

Objectives: The purpose of this study was to examine the angiographic and clinical results of stent full metal jacket in treating long lesions using everolimus-eluting stents (EES).

Background: Data are lacking regarding the use of EES for this lesion subgroup.

Methods: From 2007 to 2011, 77 symptomatic patients who had severe coronary stenoses necessitating implantation of stents with total length longer than 60 mm were treated with overlapping EES.

Results: The mean age of patient was 61 ± 11 years with male predominance (66%). Diabetes mellitus was seen in 35 (45.5%) patients. Majority of patients had class III angina with normal heart function. On average, 3.1 stents were implanted per lesion; the mean stent size and length were 2.70 ± 0.28 mm and 82 ± 16 mm. Restudy angiography was performed on 71 patients (72 lesions) at 8.9 ± 2.5 months. Angiographic restenosis was seen in 9 (12.5%) lesions; the lesion length and late loss were 67 ± 15 mm and 0.4 ± 0.6 mm, respectively. The use of intravascular ultrasound has been found to be a predictor of less restenosis (P = 0.02; HR: 0.02; CI: 0.01-0.59). The in-hospital and 1 year major adverse cardiac event rates were 7.8% and 13%. The annual cardiac death rates were 2.6%, 3.4%, and 5.3% in the first 3 years.

Conclusions: The use of EES full metal jacket for long lesions is only associated with good short-term clinical and angiographic outcomes. Long-term follow-up has revealed a high cardiac death rate which may necessitate prolongation of dual antiplatelet therapy.

MeSH terms

  • Cardiotonic Agents / administration & dosage*
  • Coronary Angiography*
  • Coronary Restenosis / epidemiology
  • Coronary Stenosis / diagnostic imaging
  • Coronary Stenosis / therapy*
  • Drug-Eluting Stents*
  • Everolimus
  • Female
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction / epidemiology
  • Sirolimus / administration & dosage
  • Sirolimus / analogs & derivatives*

Substances

  • Cardiotonic Agents
  • Everolimus
  • Sirolimus